Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 4, 2009, Pages 209-220

  Bundgaard, Christoffer ^a   Larsen, Frank ^a   Kreilgaard, Mads ^a   Brennum, Lise T ^a   Olsen, Christina Kurre ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Conditioned avoidance response; Occupancy; Pharmacodynamics; Pharmacokinetics; Sertindole

Indexed keywords

DEHYDROSERTINDOLE; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; SERTINDOLE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; RAT; RECEPTOR OCCUPANCY;

ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CELLS, CULTURED; COMPUTER SIMULATION; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INDOLES; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2;

EID: 67749114737     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.656     Document Type: Article

References (34)

1. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79: 461-479.
2. Cox EH, Langemeijer MW, Gubbens-Stibbe JM, Muir KT, Danhof M. The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. Anesthesiology 1999; 90: 535-544.
3. Ortega F, Quintana A, Suarez E, et al. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model. Pharm Res 2005; 22: 1769-1782.
4. Zuideveld KP, Rusic-Pavletic J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. J Pharmacol Exp Ther 2002; 303: 1130-1137.
5. Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and α-OH-midazolam. J Pharmacol Exp Ther 1999; 289: 1067-1074.
6. Mandema JW, Tukker E, Danhof M. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J Pharmacol Exp Ther 1992; 260: 36-44.
7. Shen WW. The metabolism of atypical antipsychotic drugs: an update. Ann Clin Psychiatry 1999; 11: 145-158.
8. Sakamoto K, Nakamura Y, Aikoh S, et al. Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism. Xenobiotica 1995; 25: 1327-1343.
9. Wong SL, Menacherry S, Mulford D, Schmitz PJ, Locke C, Granneman GR. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997; 52: 223-227.
10. Murdoch D, Keating GM. Sertindole: a review of its use in schizophrenia. CNS Drugs 2006; 20: 233-255.
11. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63-101.
12. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 1997; 154: 782-791.
13. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544.
14. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520.
15. Nyberg S, Olsson H, Nilsson U, Maehlum E, Halldin C, Farde L. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology 2002; 162: 37-41.
16. Olsen CK, Brennum LT, Kreilgaard M. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol 2008; 584: 318-327.
17. Kapur S, Vanderspek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003; 305: 625-631.
18. Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999; 23: 851-862.
19. Natesan S, Vanderspek S, Nobrega JN, McClelland RA, Kapur S. Contrasting loxapine to its isomer isoloxapine-the critical role of in vivo D2 blockade in determining atypicality. Schizophr Res 2005; 77: 189-199.
20. Wadenberg ML, Soliman A, Vanderspek SC, Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001; 25: 633-641.
21. Olsen CK, Kreilgaard M, Didriksen M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol Biochem Behav 2006; 84: 259-265.
22. Sánchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004; 77: 391-398.
23. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-371.
24. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982; 16: 143-166.
25. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165-175.
26. Didriksen M, Kreilgaard M, Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 2006; 542: 108-115.
27. Wong SL, Granneman GR. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies. J Pharm Sci 1998; 87: 1629-1631.
28. Iwata K, Ito K, Fukuzaki A, Inaki K, Haga T. Dynamin and rab5 regulate GRK2-dependent internalization of dopamine D2 receptors. Eur J Biochem 1999; 263: 596-602.
29. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423-451.
30. Subramaniam S, Lucki I, McGonigle P. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors. Brain Res 1992; 571: 313-322.
31. McGonigle P, Boyson SJ, Reuter S, Molinoff PB. Effects of chronic treatment with selective and nonselective antagonists on the subtypes of dopamine receptors. Synapse 1989; 3: 74-82.
32. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 2005; 7: E544-E559.
33. Levy G. The case for preclinical pharmacodynamics. In Integration of Pharmacokinetics, Pharmacodynamics and Toxicokinetics in Rational Drug Development, Yacobi A, Skelly JP, Shah VP, Benet LZ (eds). Plenum Press: New York, 1993; 7-13.
34. Hietala J, Kuonnamäki M, Pälvimäki EP, Laakso A, Majasuo H, Syvälahti E. Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment. Psychopharmacology 2001; 157: 180-187.